Continuous Manufacturing On Horizon As Competitive Edge In OTC Space
This article was originally published in The Tan Sheet
While OTC firms’ slimmer profit margins make equipment changes or other capital investments more difficult for them than for Rx firms, continuous manufacturing will be worth the investment, says CDER Director Janet Woodcock. “We’re going to see a lot of these out there,” she says.
You may also be interested in...
Executives say Bausch + Lomb spin-out preparations will be completed by the end of Q3. When asked, they elaborated on Carl Icahn’s acquisition of 27.8m shares, for a 7.8% stake, and expansion of the firm’s board by two seats for Icahn’s representatives.
"Now it's up to us to look where can we accelerate our portfolio, in which areas and where can we grow the most and deliver good value for our customers,” says CEO Andreas Fibig.
Jennifer Montgomery, IFF’s probiotics marketing manager for the Americas, responds to HBW Insight questions about the firm’s plans to deliver probiotics ingredients and technologies following the recent closing of its acquisition of DuPont Nutrition & Biosciences through a merger agreement.